MK-2206 2HCl

Catalog No.S1078

MK-2206 2HCl Chemical Structure

Molecular Weight(MW): 480.39

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 570 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 182 Publications

21 Customer Reviews

  • Inhibition of AKT signaling abolishes MKK4 phosphorylation on Ser78 in injured axons. Cultures of sensory neurons were treated with 5 µM MK-2206 or 5 µM GDC-0068 for 1 hr prior to axotomy. Axonal proteins harvested at indicated time points after axotomy were subjected to immunoblot analysis.

    Cell, 2015, 160(1-2): 161-76 . MK-2206 2HCl purchased from Selleck.

    j,k, Gene expression ofMYOCD (j) and ACTA2 ( SMA, k) after applying inhibitors of key components involved in the DDR2 downstream signalling pathway to HSCs cultured within 3D collagen matrix subjected to stretching (ST) (n=3, one-way ANOVA, **P=0.0036, ****P<0.0001). l,m, Expression of SMA was significantly reduced after treatment with related inhibitors in early-stage FμNs. (n=4, one-way ANOVA, ***P=0.001, ****P<0.0001). AKT-i: MK-2206

    Nature Materials, 2017, 16:1252-1261.. MK-2206 2HCl purchased from Selleck.

  • Cancer Cell 2013 24, 766-76. MK-2206 2HCl purchased from Selleck.

    The PI3K or AKT inhibition does not restore sensitivity to WZ4002 in PC9 WZR. PC9GR4 or WZR10 cells were treated with WZ4002 alone at the indicated concentrations or in combination with the AKT inhibitor MK-2206 (1 uM). MK-2206 effectively inhibited AKT in both cells.

    Cancer Discov 2012 2, 934-47. MK-2206 2HCl purchased from Selleck.

  • Rap1b negatively regulates neutrophil transcellular migration by limiting PI3K-Akt signaling. (A-D) Effect of Akt inhibitor MK2206 (2 uM), Src inhibitor PP2 (10 uM), or vehicle control (DMSO) on WT or Rap1b-/- neutrophil functions. (A) Percentage of neutrophil transendothelial migration in 3D migration model. (B) ECM degradation assessed on Oregon green-labeled gelatin matrix; (left) representative images on (bar, 10 um) and (right) bar graph is percentage of matrix degradation. (C) Percentage of cells forming multiple protrusions. (D) Percentage of neutrophils present at junction of activated bEND.3 in 3D migration assay. Mean ?SD; n = 3 independent experiments. **, P < 0.01; ***, P < 0.001; NS, not significant using unpaired Student's t test).

    J Exp Med 2014 211(9), 1741-58. MK-2206 2HCl purchased from Selleck.

    VE-cadherin-induced Akt activation mediates YAP phosphorylation and translocation in ECs. HUVECs were starved for 1h and treated with thrombin (1U) for 1h. Total cell lysates were probed with anti-pAkt, Akt or b-actin antibody. The representative blots of three independent experiments are depicted, and the normalized values for p-Akt are shown. HUVECs were cultured and starved as described as in d and incubated for 8h in complete medium with the Akt inhibitor, MK-2206 (1 uM). pAkt, Akt, pYAP and YAP were detected by western blotting using specific antibodies.

    Nat Commun 2015 6:6943. MK-2206 2HCl purchased from Selleck.

  • Inhibitors of AKT or ERK overcome SDF-1a-mediated resistance to ibrutinib-triggered PARP and caspase 3 cleavage in CXCR4S338X-expressing BCWM.1 cells. CXCR4S338X-expressing WM cells were treated with ibrutinib (0.5 uM) alone or in the presence of SDF-1a (20 nM) and/or the AKT inhibitors MK-2206 (0.5 uM) and AZD-5363 (0.5 uM); or the MEK inhibitors AS-703026 (0.25 uM), AZD-6244 (0.5 uM) and UO126 (5.0 uM). (a) Immunoblotting results for phosphoAKT (S473) and phospho-ERK (T202/Y204) in CXCR4S338X-expressing BCWM.1 cells pretreated with ibrutinib with and without AKT or ERK inhibitors, then subjected to SDF-1a stimulation for 2 min. The inhibitory effect of AZD-5363 on AKT, which is known to paradoxically hyper-phosphorylate pAKT(S473) was confirmed by inhibition of the phospho-activity for the downstream AKT targets glycogen synthase kinase 3b and pS6. (b) Immunoblotting results for cleaved PARP and cleaved caspase 3 in CXCR4S338X-expressing BCWM.1 cells treated with ibrutinib and/or AKT or ERK inhibitors for 6 h at IC50 doses. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

    Leukemia 2015 29(1), 169-76. MK-2206 2HCl purchased from Selleck.

    Induction of apoptosis positively correlates with FOXO3a protein levels and phosphorylation. (a) Treatment of 11 cell lines seeded in 6-well plates with 8 μM MK-2206 or DMSO for 48 hours. Nuclei were harvested for PI staining and FACS analysis and the differences between drug and no drug are displayed as in Figure b. Both conditions were performed in triplo for each cell line. Below the FACS data is a we stern blot of cell lysates from this panel treated with 8 μM MK-2206 or DMSO and harvested at 24 hours. Each cell line name corresponds to the two western lanes below it and the four cell cycle bars above it.

    Cancer Res 2013 73, 2189-98. MK-2206 2HCl purchased from Selleck.

  • IC50 values for an Akt inhibitor (MK-2206) and a MEK inhibitor (U0126) in a panel of mouse and human anaplastic (ATC) and follicular (FTC) carcinoma cell lines. On the bottom, a Western blotting showing the effect on the activation of Akt and ERK1/2 of one hour exposure to these inhibitors (MK-2206: 500 nM, U0126: 10 μM).

    Oncotarget 2011 2, 1109-26. MK-2206 2HCl purchased from Selleck.

    Mean IL-8 concentrations determined by ELISA of the supernatants of HeLa cells infected with wild-type Salmonella. Kinase inhibitors are indicated on the x axis, and the target families of the inhibitors are indicated above each column. CEC, chelerythrine; Pim Inh, Pim-1 inhibitor 2. Inhibitors that significantly affected IL-8 production relative to the control (P < 0.05, Bonferroni post hoc test from one-way ANOVA) are indicated with an asterisk. Relative cell viability is also shown, as determined by reduction of XTT by viable cells. A450, absorbance at 450 nm.

    Sci Signal 2011 4, rs9. MK-2206 2HCl purchased from Selleck.

  • Reducing cellular levels of PtdIns5P by overexpression of PIP4Kα inhibits clonogenic growth of U2OS but enhances cell survival in response to H2O2 stimulation. A) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), PI-103 (0.5 μM), U0126 (5 μM), or SB203580 (5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown. B) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), MK-2206 (1 μM), triciribine (1 μM), KU0063794 (1 μM), or PI-103 (0.5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown.

    FASEB J 2013 27, 1644-56. MK-2206 2HCl purchased from Selleck.

    A. Western blot analysis of pAKT activation in ovarian cancer cell lines treated with exogenous IGF-1. B. Activation of pAKT by IGF-1 in low-grade ovarian cancer cell lines was blocked by the AKT inhibitor MK-2206 in a dose-dependent manner.

    Gynecol Oncol 2011 123, 13-8. MK-2206 2HCl purchased from Selleck.

  • Confocal microscopy images of NO formation. DAF 2 DA-loaded washed platelets (1.0109 platelets/mL) were preincubated at 378C with saline (A), and then stimulated for 1min with 0.1 (B), 1.0 (C) or 10 (D) μM AEA. In Panel (E-F-G) washed platelets were preincubated with 1 μM SR1 (E), 1 Mm MK2206 (F) or 20 μM LY294002 (G), and then stimulated for 1min with 1.0 μM AEA. In panel (H) is reported the effect of 5 mg/mL collagen, used as a positive control. All the experiments were carried out in the presence of 100 μM L-arginine. NO formation was visualized by confocal microscropy as detailed in Methods.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    The AEA effect on eNOS phosphorylation. Washed platelets (1.0109 platelets/mL), preincubated at 378C with saline, 1 μM SR1, 1 μM SR2, 20 μM LY294002, 1 μM MK2206, 1.0 μM EGTA, or 30 μM BAPTA/AM, were stimulated for 1 min with 1.0 μM AEA. At the end of incubation suitable aliquots were immunoblotted with anti-p-eNOSser1177 as detailed in Methods.Blots are representative of five independent experiments.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • Effect of selected agents on NOx and cGMP formation induced by AEA. Washed platelets (1.0109 platelets/mL), prewarmed at 378C with saline or 1mM SR1, 1 μM SR2, 20 μM URB597 (URB), 1 μM MK2206 (MK) or 20 μM LY294002 (LY), were incubated for 1min with 100 μM L-arginine in the presence of 1.0 μM AEA. NOx (panel A) and cGMP (panel B) content were determined as detailed in Methods. Each bar represents the meanSD of five independent experiments carried out in triplicate. Student,s t-test: P <0.0001 versus none;P <0.0005; P <0.005 versus AEA

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    (B) Dose-response curves for DIPG 4 and SF7761 cells treated with the small molecule AKT inhibitor MK-2206 (error bars represent SEM).

    Oncol Rep, 2018, 39(2):455-464. MK-2206 2HCl purchased from Selleck.

  • C.U87MG cells were treated with vehicle or 1 μM MK-2206 for 1 hr, and then irradiated with 6 Gy. Total cell lysate was harvested 1 hr after IR and subjected to Western blot analysis with the indicated antibody. Cells without IR treatment were used as a control.

    D. Cells were treated with vehicle (control) or 1 μM MK-2206 for 1 hr, then irradiated with indicated dosage. 4 hr after IR, cells were fed with drug-free medium, and incubated for another 20 hr at 37°C, after which they were trypsinized and seeded for clonogenic survival assay. Colony-forming efficiency was determined 14 d later.
     

     

    Radiat Oncol 2009 4, 43. MK-2206 2HCl purchased from Selleck.

    MK-2206 2HCL inhibited the sorafenib-induced PI3K/mTOR pathway activation and enhanced the cytotoxic effects of sorafenib in resistant cell lines. (A) HUH-7 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved PARP were revealed by Western blotting. (B) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved RARP were revealed by Western blotting. (C) HUH-7 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (D) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. MK-2206 2HCl purchased from Selleck.

  • Comparative effects of inhibitors by immunofluorescence microscopy study. Confluent HC11 cells were grown on poly-L-lysine-coated glass coverslips (immunofluorescence) and on plastic plates (biochemical control) and then treated with inhibitors according to the standard procedure. Upper part: the biochemical action of the inhibitors was tested to validate the immunofluorescence results. Cellular proteins were analyzed by SDS-PAGE and the immunoblots were successively probed with anti-ADRP, anti-β-casein, and anti- β-actin antibodies and their respective HRP-conjugated secondary antibodies. Each experimental condition was performed in duplicate. Lower part: cells were fixed, permeabilized and subjected to immunofluorescence microscopy using antiserum against ADRP and TRITC-conjugated secondary antibody (red).

    Biochim Biophys Acta 2012 1823, 987-96. MK-2206 2HCl purchased from Selleck.

    After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of MK-2206 for 3h,followed by 15-minute stimolation of 100ng/ml EGF.

     
     

     

    Dr. Zhang of Tianjin Medical University. MK-2206 2HCl purchased from Selleck.

  •  

    PI3K pathway signaling in GDC-0941 and MK-2206 treated MCF-7 derivatives with PIK3CA or  AKT1 mutations. Cells were grown in medium containing 5% FBS and treated with vehicle or increasing concentrations of GDC-0941 (0 nM, 50 nM, 100 nM, and 400 nM) or MK-2206 (0 nM, 100 nM, 250 nM, 1000 nM). After 24 hours of drug treatment, lysates were prepared and equal amounts of protein were load ed onto SDS-PAGE gels and blotted with the indicated antibodies.

    MK-2206 2HCl purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.
Features The first allosteric small molecule inhibitor of Akt to enter clinical development.
Targets
Akt1 [1]
(Cell-free assay)		 Akt2 [1]
(Cell-free assay)		 Akt3 [1]
(Cell-free assay)
8 nM 12 nM 65 nM
In vitro

MK-2206 is an allosteric inhibitor and is activated by the pleckstrin homology domain. MK-2206 inhibits auto-phosphorylation of both Akt T308 and S473. MK-2206 also prevents Akt-mediated phosphorylation of downstream signaling molecules, including TSC2, PRAS40 and ribosomal S6 proteins. [1] MK-2206 inhibits Ras wild-type (WT) cell lines (A431, HCC827, and NCI-H292) more potently when compared to Ras-mutant cell lines (NCI-H358, NCI-H23, NCI-H1299, and Calu-6). MK-2206 also shows synergistic responses in combination with cytotoxic agents such as erlotinib or lapatinib in lung NCI-H460 or ovarian A2780 tumor cells. [2] MK-2206 or siRNA-mediated Akt inhibition strongly activates autophagy in human glioma cells. However, eukaryotic elongation factor-2 (eEF-2) silencing suppresses MK-2206-induced-autophagy, with a promotion of apoptotic cell death. [3]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H292 NVy1fFQ5S3m2b4TvfIlkKEG|c3H5 MWSzJO69VQ>? M3fSTFczKGh? M4TqR2ROW09? M17JfmlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:w M1zXNFIxPTdzME[5
A431 MkDST4lv[XOnIFHzd4F6 NXjWbZlGPSEQvF2= NXvsZmo3PSCq MkXmSG1UVw>? MmLZV5VxeHKnc4Pld{B1cGVic3nncoFtcW6pIH;mJGFsfCCjbnSgSZJs MUCyNFU4OTB4OR?=
HepG2 MWPDfZRwfG:6aXOgRZN{[Xl? MlfMNVAh|ryP MmTYNlQhcA>? MWjEUXNQ M1uxOXNmdnOrdHn6[ZMhemW|aYP0ZY51KGOnbHzzJJRwKHSqZTDjfZRwfG:6aXOg[YZn\WO2IH;mJJNwemGoZX7pZi=> MX:yNVIxPTl{NR?=
Sk-Hep1 M1zPU2N6fG:2b4jpZ{BCe3OjeR?= NF;E[G0yOCEQvF2= NHnURlczPCCq M4juNWROW09? NW\Oc3k5W2Wwc3n0bZpmeyC{ZYPpd5RidnRiY3XscJMhfG9idHjlJIN6fG:2b4jpZ{Bm\m[nY4Sgc4Yhe2:{YX\lcolj NYPvZmM4OjF{MEW5NlU>
OCUT1 cells harbored PIK3CA (H1047R+/+) NYPk[mVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPPXoc{KM7:TR?= M4nvfFUh\A>? MVTEUXNQ MUTJR|UxRTBwMUSg{txO NETkNIUzOTJ6OUK2Oy=>
K1 cells harbored PIK3CA (E542K+/+) M3:zfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;6WFMh|ryP MkmzOUBl NXK1UY5HTE2VTx?= MVjJR|UxRTBwNUKg{txO M4fCOVIyOjh7Mk[3
FTC133 cells harbored PTEN (allele deletion and R130+) NUDpUWFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LSd|Mh|ryP M17HPVUh\A>? M163fmROW09? NWj2cmNHUUN3ME2wMlE5KM7:TR?= M3LK[lIyOjh7Mk[3
C643 cells harbored HRAS (G13R+/−) MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jFN|Mh|ryP NYW1cYJDPSCm NEfIZ3BFVVOR MYLJR|UxRTBwMkeg{txO M1ixeVIyOjh7Mk[3
Hth7 cells harbored NRAS (Q61R+/−) M{fQZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFe0W3M{KM7:TR?= MWW1JIQ> M4Hqd2ROW09? NXrLeVFSUUN3ME20MlUh|ryP MVOyNVI5QTJ4Nx?=
TPC1 cells harbored RET/PTC1 rearrangement MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[0N{DPxE1? M3LLcVUh\A>? NYi2TXNbTE2VTx?= NH7DNlVKSzVyPUCuOVkh|ryP M1PuXVIyOjh7Mk[3
Hth74 M1y1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LiVVMh|ryP NXe0OZVQPSCm M1ztU2ROW09? MWHJR|UxRTJwMUmg{txO MVeyNVI5QTJ4Nx?=
KAT18 MnXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIqwb2c{KM7:TR?= NYO4NoN5PSCm M3LOemROW09? MUDJR|UxRTRwNkKg{txO MV2yNVI5QTJ4Nx?=
SW1736 NVXHS4VXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUmxNFAh|ryP NWHnbGlSPSCm MnTVSG1UVw>? NHLiZXRKSzVyPUS3MlU3KM7:TR?= MUmyNVI5QTJ4Nx?=
WRO MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrjdpJrOTByMDFOwG0> NHvrc4Q2KGR? NW[xfVdzTE2VTx?= NF[zbmlKSzVyPkGwNFAh|ryP MoDZNlEzQDl{Nke=
TAD2 NYGwfHpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVSxNFAxKM7:TR?= NVnvfphSPSCm MX7EUXNQ M4P2Z2lEPTB-MUCwNEDPxE1? NFqwOXkzOTJ6OUK2Oy=>
LN229 Mn3XRZBweHSxc3nzJGF{e2G7 MWOwMlUh|ryP MUS2NEBp MVfEUXNQ MX\BeYdu\W62czDhdI9xfG:pZX7pZ{Bm\m[nY4TzJI9nKGenZnn0bY5q[g>? NITIeYwzOjB3N{mxOC=>
T98G MofaRZBweHSxc3nzJGF{e2G7 MWSwMlUh|ryP NUm0UJZvPjBiaB?= MWPEUXNQ NYW5dFFCSXWpbXXueJMh[XCxcITv[4VvcWNiZX\m[YN1eyCxZjDn[YZqfGmwaXK= MYSyNlA2PzlzNB?=
HC11 M{nvR2Z2dmO2aX;uJGF{e2G7 MVKxNEDPxE1? MoCxNlQhcA>? M1j4cWROW09? M1S4fWlvcGmkaYTzJO6zNWOjc3XpckBidmRiQVTSVEB{gW62aHXzbZM> NI\mbGgzOjR{Nk[yNS=>
MOLT-4 NUfZS|ZiS3m2b4TvfIlkKEG|c3H5 M2qxTlExKM7:TR?= M3ztNlQ5KGh? NF\Bc2hFVVOR NF\jZopKSzVyPUGuO-KBkc7:TR?= MXuyNlYyPDJ2Mx?=
CEM-R MlG3R5l1d3SxeHnjJGF{e2G7 M4qxOlExKM7:TR?= M4jTbFQ5KGh? MnrISG1UVw>? Mn;LTWM2OD1|LkRihKnPxE1? MWSyNlYyPDJ2Mx?=
CEM-S NVPrcYN{S3m2b4TvfIlkKEG|c3H5 NVL5XmJtOTBizszN NHvYV2M1QCCq M4rzRWROW09? NIP2NoxKSzVyPUWuNgKBkc7:TR?= MVmyNlYyPDJ2Mx?=
MOLT-4 NEDpVWFHfW6ldHnvckBCe3OjeR?= NVPpPIVCOTBizszN M2fz[FI1KGh? M4XYNmROW09? NEjEV2xDdG:la4OgZ4VtdHNiaX6geIhmKEdyL1exJJBp[XOnIH;mJJRp\SClZXzsJIN6[2yn NHjSWnkzOjZzNEK0Ny=>
MOLT-4 MoXzSpVv[3Srb36gRZN{[Xl? NHnpTW816oDLzszN MnrhOEBp MXLEUXNQ MXvJcoNz\WG|ZYOgeIhmKGGvb4XueEBw\iClbHXheoVlKEyFM1GvRkwh[SC5ZXzsMYV{fGGkbHnzbIVlKGG3dH;wbIFogSCvYYLr[ZI> MXqyNlYyPDJ2Mx?=
CEM-R NFm5W4dHfW6ldHnvckBCe3OjeR?= Mnu0OQKBkc7:TR?= NH3kV4g1KGh? NXnGRZo{TE2VTx?= NYLkNnE{UW6lcnXhd4V{KHSqZTDhcY92dnRib3[gZ4xm[X[nZDDMR|RCN0JuIHGge4VtdC2nc4ThZoxqe2inZDDheZRweGijZ4mgcYFzc2W{ M{jEXVIzPjF2MkSz
CEM-S M{W2S2Z2dmO2aX;uJGF{e2G7 M4rSRlTjiIoQvF2= NWXW[2dkPCCq NX\hdmxDTE2VTx?= NFPDco1KdmO{ZXHz[ZMhfGinIHHtc5VvfCCxZjDjcIVifmWmIFzDOWEwSixiYTD3[YxtNWW|dHHicIl{cGWmIHH1eI9xcGGpeTDtZZJs\XJ? M2fnWVIzPjF2MkSz
HepG2 cell Mk\jT4lv[XOnIFHzd4F6 NVnnbZlTOjBizszN MUeyOEBp M{e5VGROW09? MVLEc5dvemWpdXzheIV{KHSqZTDwbI9{eGixconsZZRqd25ib3[gRWtV NYCyZog2OjN5OUezNVk>
HepG2 cell NEnIOY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV6zNEDPxE1? NV7HWYJwOjRiaB?= MWjEUXNQ NFG1dodKdmirYnn0d{Bk\WyuIHfyc5d1cA>? Mlz2NlM4QTd|MUm=
HepG2 cell NWLFdpl1SXCxcITvd4l{KEG|c3H5 MkX2NlAh|ryP NHHwN3kzPCCq M1T2dGROW09? M4LEVGlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NFzHPIkzOzd7N{OxPS=>
GEO MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUC1NFAhdk1? MVu3NkBp NWX1T|FVTE2VTx?= MUDJcohq[mm2czDj[YxtKGe{b4f0bC=> NFTvXXczPDV6MUKzNS=>
CNE-1 M1zuc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIj2O24yOCEQvF2= MWG5OkBp NVfoSnRZTE2VTx?= MlnNTWM2OD1{Lkm2JO69VQ>? MUOyOVM{Pjl{NR?=
CNE-2 M360fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7UfHI6OTBizszN NHXzUow6PiCq NGPxVYxFVVOR MoL6TWM2OD12LkWzJO69VQ>? MnTINlU{OzZ7MkW=
HONE-1 M4DLfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NID3RYUyOCEQvF2= M{LieVk3KGh? Mk\kSG1UVw>? NXTxUIdnUUN3ME2zMlM4KM7:TR?= NWHsNnV[OjV|M{[5NlU>
SUNE-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXz1W5M2OTBizszN M1OwNVk3KGh? M3TSemROW09? M1jQZmlEPTB;MD61NkDPxE1? MXKyOVM{Pjl{NR?=
CNE-2 M2K2ZWZ2dmO2aX;uJGF{e2G7 NFzEUIYyOCEQvF2= NWfPTHlSPDhiaB?= MkezSG1UVw>? MoDLTY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDheEBIOQ>? NGjQUY8zPTN|NkmyOS=>
HONE-1 NYTTdXVwTnWwY4Tpc44hSXO|YYm= NHvvfHYyOCEQvF2= NGXNPXQ1QCCq MWLEUXNQ M{DKbGlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZZQhTzF? NGG5RZczPTN|NkmyOS=>
NEC8 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUL0ZoVCUUN3ME2wMlA6PjVzIN88US=> MUjTRW5ITVJ?
P12-ICHIKAWA MlXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTBwMUG2NkDPxE1? M2\NdHNCVkeHUh?=
MDA-MB-175-VII NH7rS|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXH3VppzUUN3ME2wMlE{PzN6IN88US=> MVvTRW5ITVJ?
AsPC-1 M1K4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHiTWM2OD1yLkKyNVIzKM7:TR?= M4r6WXNCVkeHUh?=
T47D MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwMkiyOUDPxE1? Mnq1V2FPT0WU
HH NFvpOHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHK0VZpKSzVyPUCuN|AzQDNizszN M2nwSXNCVkeHUh?=
MOLT-16 MlSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXMcpNKSzVyPUCuN|A{OiEQvF2= MYLTRW5ITVJ?
ES5 MkTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDmeohKSzVyPUCuN|Q1PTVizszN M1fTRXNCVkeHUh?=
RS4-11 NITYT|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDQOJpDUUN3ME2wMlM1PjFizszN NWi2dpU1W0GQR1XS
KARPAS-45 M{fWWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXPRlhKSzVyPUCuN|c{OjFizszN Mn;6V2FPT0WU
NCI-H720 NXf4U5RZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUntTGZVUUN3ME2wMlM4Pjd7IN88US=> MlzYV2FPT0WU
H9 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTMSWhwUUN3ME2wMlM5QDh|IN88US=> M{\QXXNCVkeHUh?=
EFM-19 M3;6d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnm3TWM2OD1yLkS0NFEh|ryP NWLZbHJOW0GQR1XS
SBC-1 M13JUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4D6dWlEPTB;MD60OFA{PSEQvF2= MYnTRW5ITVJ?
A4-Fuk NYjk[2hMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjicopLUUN3ME2wMlQ3QDZ6IN88US=> MnzjV2FPT0WU
NCI-H1563 NGmycIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;GTWlEPTB;MD60PFE5QSEQvF2= NVL6VWo4W0GQR1XS
HCC1419 NUP2XllTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwNEi4PVIh|ryP M3vueHNCVkeHUh?=
H-EMC-SS M1nLUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3YRnBnUUN3ME2wMlQ6QTN7IN88US=> NWe3W3hvW0GQR1XS
BHT-101 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\5T|N2UUN3ME2wMlUzQTZzIN88US=> MYLTRW5ITVJ?
IGROV-1 M2X5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\yb4k3UUN3ME2wMlU2OjR7IN88US=> MVvTRW5ITVJ?
HGC-27 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDMTWM2OD1yLkW2O|g{KM7:TR?= M1zPT3NCVkeHUh?=
MDA-MB-361 MlvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjyToRKSzVyPUCuOVc4PjFizszN NUWzO2lwW0GQR1XS
KE-37 NXvDfIp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHvTWM2OD1yLkW4NlYh|ryP M1LPWnNCVkeHUh?=
HCC70 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGr0eW9KSzVyPUCuOVk5OjdizszN MXfTRW5ITVJ?
LNCaP-Clone-FGC M1PYZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTWTWM2OD1yLk[xNFQ5KM7:TR?= NF3GSVNUSU6JRWK=
HAL-01 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLZTWM2OD1yLk[yNVMh|ryP NFz2SoVUSU6JRWK=
HT NF\FSIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXUTWM2OD1yLk[zNlM6KM7:TR?= NIOxSmFUSU6JRWK=
MDA-MB-415 MnTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPXd2dLUUN3ME2wMlY{PjJ4IN88US=> MYDTRW5ITVJ?
NOS-1 M1vyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvyTWM2OD1yLk[zO|I{KM7:TR?= NYLIeFl6W0GQR1XS
DU-145 NWjDW5hKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnIVJhKSzVyPUCuOlQ4PDVizszN NFHPU3ZUSU6JRWK=
OCUB-M NV7rOWJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTHTWM2OD1yLkewPVY3KM7:TR?= NHjub|NUSU6JRWK=
VA-ES-BJ MmS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjJe|VKSzVyPUCuO|MxOjVizszN M4ixOXNCVkeHUh?=
J-RT3-T3-5 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFf4fnpKSzVyPUCuO|Q1ODNizszN NUnH[48xW0GQR1XS
MOLT-4 M1\yfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fXO2lEPTB;MD64NFU5OiEQvF2= NY\wO|AxW0GQR1XS
NB7 MkDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fVdWlEPTB;MD64NlQyOSEQvF2= NXPCTVJoW0GQR1XS
L-363 NEjHSm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DhRmlEPTB;MD64N|Q1OiEQvF2= M1n3eXNCVkeHUh?=
NKM-1 NWrnWW5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Gzc2lEPTB;MD64OlI2OyEQvF2= NEHwVlJUSU6JRWK=
HOP-92 NH75UY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Li[GlEPTB;MD64O|IzOyEQvF2= MlPZV2FPT0WU
OAW-42 NEOy[XNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwOEi3NkDPxE1? NGTpO3hUSU6JRWK=
HuO9 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{X4T2lEPTB;MD65Nlc2OSEQvF2= NVfzfIVVW0GQR1XS
MFE-280 NGHRXI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHy1doRKSzVyPUCuPVY1PjVizszN M2LONHNCVkeHUh?=
EM-2 M12wSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXKwVJZPUUN3ME2wMlk4QTN7IN88US=> M2i4VXNCVkeHUh?=
NCI-H520 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwOUi1PVIh|ryP NUL1[W1mW0GQR1XS
LB2241-RCC NUixSFlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{P6TGlEPTB;MD65PVc{PCEQvF2= MUnTRW5ITVJ?
SK-NEP-1 MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjEZZBKSzVyPUGuNVQ1QDVizszN MYjTRW5ITVJ?
LXF-289 NV;hVlQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHmZWVFUUN3ME2xMlE4OTV4IN88US=> MmntV2FPT0WU
EPLC-272H NYXHWIk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkT1TWM2OD1zLkG3NlU3KM7:TR?= M37BVnNCVkeHUh?=
COLO-684 NYjubItKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTFwMkO3NlUh|ryP NHu2c3JUSU6JRWK=
ES1 NF30Wo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{f3NmlEPTB;MT6yOFA3PSEQvF2= NUXIbVZCW0GQR1XS
DOHH-2 MkfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonPTWM2OD1zLkK4NlA{KM7:TR?= NVLPOYc3W0GQR1XS
CTB-1 MnzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH6xV3ZKSzVyPUGuNlg6QSEQvF2= NYD5fIREW0GQR1XS
G-401 NGX2W5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTFwMkm3PVUh|ryP Ml\RV2FPT0WU
LoVo MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTFwM{K1N|Qh|ryP M{PmTXNCVkeHUh?=
Ramos-2G6-4C10 NEOxSGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTFwM{O3NFEh|ryP MX3TRW5ITVJ?
MFM-223 MonlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXS1SFAyUUN3ME2xMlM1PDZzIN88US=> MojDV2FPT0WU
PA-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XxV2lEPTB;MT6zOVI3PSEQvF2= NGDCcnBUSU6JRWK=
697 M2q0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;zUohSUUN3ME2xMlM4PjF4IN88US=> NE\QNnRUSU6JRWK=
QIMR-WIL NGDESGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzGV5lKSzVyPUGuOFkyOTZizszN Mly5V2FPT0WU
HOS MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3yTWM2OD1zLkS5OVU5KM7:TR?= NGfh[JpUSU6JRWK=
DMS-273 M2XJTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLsPGhzUUN3ME2xMlUyQTV7IN88US=> MlLSV2FPT0WU
ME-180 MnjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLBeWJKSzVyPUGuOVY5QTFizszN MVfTRW5ITVJ?
HCC2218 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTFwNkiyNlUh|ryP NFfZOIVUSU6JRWK=
CAL-54 NGn2XopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTFwN{GyOFIh|ryP NUjUO4JTW0GQR1XS
OMC-1 NYC3XHBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLJTWM2OD1zLke0Olc4KM7:TR?= M33HU3NCVkeHUh?=
COR-L105 NY\QSYdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTFwN{m3N|ch|ryP MYrTRW5ITVJ?
BV-173 MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLrTWM2OD1zLkixNFc1KM7:TR?= M37lVHNCVkeHUh?=
RKO M1O2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDYO4VsUUN3ME2xMlg4OTBzIN88US=> M1PVb3NCVkeHUh?=
SNU-387 NHLMVmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvFTWM2OD1zLki4OFA3KM7:TR?= M4C0WnNCVkeHUh?=
SW1088 NX7OOnZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEX0blNKSzVyPUGuPVQ3ODZizszN NXyzRpdsW0GQR1XS
Hs-578-T M3PQTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DPUmlEPTB;Mj6xNVQ{OyEQvF2= MUXTRW5ITVJ?
OC-314 MlrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTJwMUWwPFYh|ryP MV7TRW5ITVJ?
RMG-I M2\kZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlGyTWM2OD1{LkG2N|k5KM7:TR?= NGP5TJlUSU6JRWK=
NCI-H1395 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml71TWM2OD1{LkG4NFkyKM7:TR?= M1v0b3NCVkeHUh?=
GAMG MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTJwMkO4OFUh|ryP NFq1SG1USU6JRWK=
LB1047-RCC MoLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;4TWM2OD1{LkK0N|E4KM7:TR?= MoHqV2FPT0WU
MN-60 MlKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HvVmlEPTB;Mj6yPVkzOyEQvF2= M4rnPXNCVkeHUh?=
OAW-28 NXLQTHJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWH0Umk3UUN3ME2yMlI6QTVzIN88US=> NIL6TppUSU6JRWK=
NCI-H2228 NHH5Z|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\4PHRKSzVyPUKuN|E2PTJizszN MUDTRW5ITVJ?
ABC-1 NVLpenJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DrW2lEPTB;Mj6zN|I2OyEQvF2= M3rMd3NCVkeHUh?=
LS-513 M{jDZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvXRVdKSzVyPUKuN|M1QDRizszN MUnTRW5ITVJ?
KS-1 NX;oUHE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWP0NWFUUUN3ME2yMlM5OTlzIN88US=> M3nacHNCVkeHUh?=
NB69 NE\tR4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHtUXdKSzVyPUKuN|g6QDNizszN NIK0OFVUSU6JRWK=
VM-CUB-1 M1Szemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnxTWM2OD1{LkO5NFg{KM7:TR?= M{nkc3NCVkeHUh?=
D-423MG MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTJwNEGwOFQh|ryP MVrTRW5ITVJ?
EW-18 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\S[mlEPTB;Mj60NVk{QSEQvF2= NUO5SW86W0GQR1XS
YH-13 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTJwNE[xOVMh|ryP NYTw[oFRW0GQR1XS
T-24 MnfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTJwNEe4PFEh|ryP M3jlW3NCVkeHUh?=
ES8 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnoUm9GUUN3ME2yMlQ6Ojh5IN88US=> MnjvV2FPT0WU
ES3 NVfHW5VRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7uTWM2OD1{LkS5O|U6KM7:TR?= NFT1d4RUSU6JRWK=
RXF393 NUXU[VM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7lc4ZKSzVyPUKuOlA1QDdizszN M{PHRXNCVkeHUh?=
RPMI-8226 NFT4ZndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXQTWM2OD1{Lk[yPVU{KM7:TR?= NWO4Z2JxW0GQR1XS
AGS MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHFcpJKSzVyPUKuO|IyOzdizszN MlTHV2FPT0WU
HCC1395 Mkf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTJwN{WxPFch|ryP MmDLV2FPT0WU
MV-4-11 Mor6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTJwN{WyOlYh|ryP M33yTXNCVkeHUh?=
A204 MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\wUZVKSzVyPUKuPFM5PzJizszN MmH6V2FPT0WU
MCF7 MljJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfafnRLUUN3ME2yMlg3OTF5IN88US=> MUHTRW5ITVJ?
SNU-423 M2Hmdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfRTWM2OD1{Lki5NlQzKM7:TR?= NWrvbGpzW0GQR1XS
NCI-H1048 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPyTWM2OD1{Lkm2PFY2KM7:TR?= M4OwUXNCVkeHUh?=
GR-ST NWD1XohoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPjTWM2OD1|LkC0OlEyKM7:TR?= NInKepZUSU6JRWK=
EoL-1- NUHwWYNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTNwMEewOVgh|ryP NXiyU3VxW0GQR1XS
HuH-7 NWTCTVF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTDNGVKSzVyPUOuNFk1PjRizszN MYLTRW5ITVJ?
OS-RC-2 MoT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLpTWM2OD1|LkGxNVkh|ryP MXPTRW5ITVJ?
EW-3 NUHJVlN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jBdWlEPTB;Mz6xPVUzQSEQvF2= NYT1U2xGW0GQR1XS
NCI-H747 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4S5RWlEPTB;Mz6yNFY6PCEQvF2= NEG2TmpUSU6JRWK=
EW-16 NFz3UnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmj0TWM2OD1|LkKxPFc6KM7:TR?= M2rDcXNCVkeHUh?=
DOK MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn2xTWM2OD1|LkKyPFU6KM7:TR?= MUfTRW5ITVJ?
HCC2157 NHjvU3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTNwM{ixO|kh|ryP NXHEZ2hRW0GQR1XS
OVCAR-3 NIniR4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzoZWI5UUN3ME2zMlQxPzh4IN88US=> NXzZWIFjW0GQR1XS
NCI-H1623 NVnWdIUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTNwNEGyNlQh|ryP NWDrOFBXW0GQR1XS
H4 Mo\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW[2S5BVUUN3ME2zMlQ2PjJ4IN88US=> NHzRdJNUSU6JRWK=
SW1710 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7zdVVNUUN3ME2zMlQ3Pjd6IN88US=> Mlz4V2FPT0WU
RT-112 M3HnN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLIW4hKSzVyPUOuOVI{QDhizszN NH;HVJlUSU6JRWK=
DMS-114 M1nlWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTNwNkKyO|gh|ryP M4LtZnNCVkeHUh?=
AN3-CA M3;3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\1XnBKSzVyPUOuOlI1PTZizszN NVTXVXV6W0GQR1XS
KNS-62 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnwR4Z2UUN3ME2zMlY{OzN6IN88US=> M3LZOnNCVkeHUh?=
SJRH30 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTNwNkmxNlIh|ryP MX\TRW5ITVJ?
G-402 Mn[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljuTWM2OD1|LkewO|EyKM7:TR?= M{PFdXNCVkeHUh?=
MHH-PREB-1 NGfmXlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTNwN{KwN|gh|ryP NUHiSldsW0GQR1XS
P30-OHK M1zINmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TqVmlEPTB;Mz64NFk4PiEQvF2= NUOxe4hmW0GQR1XS
RVH-421 NUDNbWt2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\BOnc2UUN3ME2zMlgyPzh6IN88US=> NGnSTG9USU6JRWK=
LU-134-A NVXHSGVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonaTWM2OD1|Lki4OFI5KM7:TR?= NYfpXIFvW0GQR1XS
ECC10 M1LiV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nxZ2lEPTB;Mz65N|YzOiEQvF2= Mk[yV2FPT0WU
TGW NGDjXJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\xSmlEPTB;ND6wNlMxPSEQvF2= NGrQWVdUSU6JRWK=
MLMA MmXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Lsb2lEPTB;ND6wNlk3PiEQvF2= Mn3QV2FPT0WU
SCC-25 NUfM[mY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M322N2lEPTB;ND6wOlU3PiEQvF2= MYDTRW5ITVJ?
TYK-nu MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTRwMEm1N|Qh|ryP NFz1d2VUSU6JRWK=
LAMA-84 MnXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfrTWM2OD12LkG0NVkyKM7:TR?= MYPTRW5ITVJ?
Calu-3 NVHmNppVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHX5NWdKSzVyPUSuNlQ1OTZizszN NHnKdZBUSU6JRWK=
NCI-H460 MofrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37qU2lEPTB;ND6yOlQ1OyEQvF2= M{i5eHNCVkeHUh?=
EGI-1 NVTqbGZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfjO4dKSzVyPUSuN|c4PzhizszN NIXafoVUSU6JRWK=
NCI-H292 NYf3c3ExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjpUJpKSzVyPUSuN|gyPDZizszN MYnTRW5ITVJ?
HCE-T MnHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PWb2lEPTB;ND60NVU4QSEQvF2= MYPTRW5ITVJ?
EW-11 NFn4ZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXmzV29ZUUN3ME20MlQyQDN6IN88US=> MVHTRW5ITVJ?
ATN-1 NYjWUJRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkC3TWM2OD12LkS0N|A1KM7:TR?= MVnTRW5ITVJ?
NB5 Ml7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGO4cZVKSzVyPUSuOVM3QTdizszN MlvSV2FPT0WU
KLE M3LKRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfK[nljUUN3ME20MlcxOTl6IN88US=> MUTTRW5ITVJ?
CAL-39 M4XPRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrYTWM2OD12LkeyNVQ3KM7:TR?= NUjiO2JyW0GQR1XS
TI-73 MoPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUWxepY{UUN3ME20MlgxPjB7IN88US=> M4HvOnNCVkeHUh?=
HO-1-N-1 MkLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTRwOUSyJO69VQ>? NYjXUHJOW0GQR1XS
786-0 NUjabVd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfKTWM2OD12Lkm0Olc{KM7:TR?= M324SXNCVkeHUh?=
SK-N-DZ M1rNUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zJWmlEPTB;ND65OlE1OiEQvF2= NHzsTGZUSU6JRWK=
NCI-H446 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3z4eGlEPTB;NT6yNFAxQSEQvF2= MVLTRW5ITVJ?
ETK-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLVTWM2OD13LkKxNVY2KM7:TR?= NIjtdWVUSU6JRWK=
BT-20 NGTYN4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlr2TWM2OD13LkKxN|U{KM7:TR?= NGTrXm1USU6JRWK=
MEL-HO MmXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTYTWM2OD13LkO3N|M3KM7:TR?= NX7KW3JLW0GQR1XS
CAL-27 M{XJdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLmTWM2OD13LkS2N|M6KM7:TR?= Ml2zV2FPT0WU
SW872 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPyZnlKSzVyPUWuOVk1OjhizszN M3XzUnNCVkeHUh?=
RPMI-2650 M1TBb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fBVWlEPTB;NT62OlE6QSEQvF2= NV:xRpdsW0GQR1XS
PFSK-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\vXWlEPTB;NT63Nlc{OiEQvF2= MmLaV2FPT0WU
SF295 MmTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHSySpVKSzVyPUWuPFA3OzNizszN MlvNV2FPT0WU
Becker M4HGSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkL1TWM2OD13Lki2OFczKM7:TR?= NGS3OG1USU6JRWK=
Saos-2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vFOmlEPTB;NT64OlU{KM7:TR?= NV\HenVLW0GQR1XS
SK-OV-3 NVz6N5RZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTqTWM2OD13Lkm5PFE3KM7:TR?= NFzUW4xUSU6JRWK=
VMRC-RCZ M4jWfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDNTWM2OD14LkC4O|c{KM7:TR?= NELKeoRUSU6JRWK=
EW-22 NHnRNpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\UTWM2OD14LkG5OlQ6KM7:TR?= NGKxNIVUSU6JRWK=
BT-474 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTZwMkOzJO69VQ>? MmDFV2FPT0WU
BFTC-909 NX7GToI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLS[olDUUN3ME22MlMxOzR3IN88US=> Mne4V2FPT0WU
NB12 NWXOV3htT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEX6W2pKSzVyPU[uN|kxPzFizszN NYrC[HhmW0GQR1XS
D-263MG NGC4VmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH21OZdKSzVyPU[uOFUyPjlizszN NXntfYF7W0GQR1XS
SNB75 NXvpV4xjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7JenlKSzVyPU[uOlAyPDNizszN M{DJPHNCVkeHUh?=
A704 NVHxbll[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoL5TWM2OD14Lk[zNFYh|ryP MWnTRW5ITVJ?
NCI-H1693 MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjETWM2OD14Lk[zOlA1KM7:TR?= NHHNUJJUSU6JRWK=
LN-405 MnzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HJe2lEPTB;Nj63PVY4OiEQvF2= MlXYV2FPT0WU
CHL-1 M4fWbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTZwOECwO|kh|ryP Ml:2V2FPT0WU
A498 NEn1fXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzEUWd6UUN3ME22MlgyQTZzIN88US=> NVr3O3RzW0GQR1XS
TE-12 M3LS[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTZwOEO4NVch|ryP M3TEUnNCVkeHUh?=
TE-6 NHnJe3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDPW2pKSzVyPU[uPVMxOzhizszN NYPEUGxIW0GQR1XS
AU565 NHTNNGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTZwOU[5OVch|ryP NH\te5lUSU6JRWK=
RD NYTuRohnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PuVWlEPTB;Nj65PFI5PCEQvF2= M1nPNnNCVkeHUh?=
SW1463 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTdwMUGxOlgh|ryP MWnTRW5ITVJ?
LU-99A MmTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;QRWFKSzVyPUeuNVQ{OjJizszN MmLiV2FPT0WU
NCI-H28 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mon6TWM2OD15LkK5NlQh|ryP NVvGUXBEW0GQR1XS
MC-IXC MlG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moj0TWM2OD15LkS4OVc3KM7:TR?= NFvxVWJUSU6JRWK=
GP5d NEfN[|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPDS4dKSzVyPUeuOFg4PjRizszN NXTOfI5kW0GQR1XS
GB-1 NWfyfVROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\JU2lEPTB;Nz61OFgxPCEQvF2= NXWxc2dTW0GQR1XS
CAL-33 MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTdwNk[yN|Mh|ryP Mnv3V2FPT0WU
MSTO-211H M4f0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonHTWM2OD15Lk[3N|M3KM7:TR?= MkXwV2FPT0WU
TE-5 MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLMTWM2OD15Lke5N|M1KM7:TR?= MmqxV2FPT0WU
D-566MG Mlu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rRcGlEPTB;OD6wOFQzQSEQvF2= MkHkV2FPT0WU
JVM-3 MmC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRThwMUWyOlgh|ryP M2DuOXNCVkeHUh?=
T98G MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33vVWlEPTB;OD6xPFA3PyEQvF2= MomzV2FPT0WU
HCC1954 M3jJZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDXeGRKSzVyPUiuOFUyODRizszN NFPRbJJUSU6JRWK=
SF126 NFL2eoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjVOpVKSzVyPUiuOFU6OzZizszN M4PGXXNCVkeHUh?=
LB996-RCC NETvN5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjMRoFrUUN3ME24MlU{OjV5IN88US=> NGTFS25USU6JRWK=
SKG-IIIa NX;3bVJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4j0NGlEPTB;OD62N|A3QSEQvF2= MYnTRW5ITVJ?
NCI-SNU-1 M2r0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nJPGlEPTB;OD62OFY1OyEQvF2= MXfTRW5ITVJ?
LB771-HNC MknLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrKcJo5UUN3ME24MlY1Pjl4IN88US=> NV3sUoxLW0GQR1XS
SCC-4 MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRThwNkiyNVkh|ryP MXnTRW5ITVJ?
CAMA-1 NHzmcllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoW4TWM2OD16Lke3NVQ3KM7:TR?= NHXhTmZUSU6JRWK=
D-502MG NUPtUIFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRThwN{i2Nlkh|ryP M4D0fHNCVkeHUh?=
ESS-1 NYH4VJdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRThwOEi3NFQh|ryP NEDzS4tUSU6JRWK=
HEC-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXLNmQ1UUN3ME24Mlg6QDZ4IN88US=> MmnNV2FPT0WU
NB10 Ml3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFOxO2JKSzVyPUmuNFIzOjRizszN NX\2OGtXW0GQR1XS
8505C NInPNYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTlwMESyN|Ih|ryP NUHUWWE6W0GQR1XS
EFO-27 M3z6RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHrTohKSzVyPUmuNVY1OTJizszN M4[3O3NCVkeHUh?=
HN NUS5OpJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUS4R3FmUUN3ME25MlE3PjJ6IN88US=> MXLTRW5ITVJ?
DSH1 NIO1RpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTlwMkC4O{DPxE1? M3fMS3NCVkeHUh?=
NBsusSR NEjXVW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrkV5R1UUN3ME25MlI4PDB{IN88US=> M4LQ[XNCVkeHUh?=
LS-123 NUTNVlVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3PTWM2OD17LkOxO|YyKM7:TR?= M2\IW3NCVkeHUh?=
SHP-77 NHjQSnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGD4OohKSzVyPUmuN|k6OzVizszN NWXmS21zW0GQR1XS
ACN MkXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTlwNUOyO|ch|ryP MorCV2FPT0WU
U251 NWfkVI5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XC[GlEPTB;OT62OVU1PCEQvF2= NEDjO2VUSU6JRWK=
A431 NIT3RXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTlwOECyN|gh|ryP NIntdmdUSU6JRWK=
5637 NGiyW4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX23N45{UUN3ME25Mlg1QTh2IN88US=> M1vBN3NCVkeHUh?=
MDA-MB-157 NVz4eGViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnhOVdqUUN3ME25MlkzQDd6IN88US=> MlfCV2FPT0WU
A101D NHXTd5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTlwOUm5O|Qh|ryP NU\ySJljW0GQR1XS
YKG-1 M4DGXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrsO|FKSzVyPUGwMlIxODZizszN MlG4V2FPT0WU
LAN-6 M1fZbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnm4TWM2OD1zMD6yNVY1KM7:TR?= NFvoXXJUSU6JRWK=
OVCAR-5 M{LsSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHC[WxVUUN3ME2xNE4zPDN|IN88US=> M3\IXXNCVkeHUh?=
A549 NH2ydWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTFyLkO5O|Mh|ryP M37HSHNCVkeHUh?=
no-11 NEHOb5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHGWINKSzVyPUGwMlQ{PTNizszN NWPCZVBzW0GQR1XS
SF539 M3TjeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XTXGlEPTB;MUCuPVA1OSEQvF2= MoHtV2FPT0WU
A388 M2fOTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoS0TWM2OD1zMT6zPFk4KM7:TR?= M3TKNnNCVkeHUh?=
DEL MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYGyNnloUUN3ME2xNU41OjRizszN NYP0UphHW0GQR1XS
SW954 M4rXOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPqV4IyUUN3ME2xNU41PjZ6IN88US=> NXPMXWVGW0GQR1XS
TK10 NYW1U5lkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTFzLkWyO|Eh|ryP NVLNbmdpW0GQR1XS
SW756 NV7aW2t4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHP0dVVKSzVyPUGxMlUzQTRizszN NWTZ[Y1DW0GQR1XS
PC-3 M3Tn[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\MNmlEPTB;MUGuOVc3PCEQvF2= NFHRWXpUSU6JRWK=
ONS-76 MonuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jqN2lEPTB;MUGuOlM3KM7:TR?= M{nVV3NCVkeHUh?=
A427 NF\MNZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWGxN|A3UUN3ME2xNU44ODl|IN88US=> NEjvdnRUSU6JRWK=
MEG-01 NXrvNm5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTOPItKSzVyPUGxMlc2ODlizszN MUPTRW5ITVJ?
BB30-HNC MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILWNlVKSzVyPUGxMlc6QDJizszN Mn\pV2FPT0WU
NCI-H1299 MnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrIWoZKSzVyPUGxMlgxQTNizszN M2q3WXNCVkeHUh?=
GCT M1TJcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTFzLkiyNlgh|ryP NYPaVG15W0GQR1XS
D-247MG NEP5N5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rpfGlEPTB;MUGuPVY3OyEQvF2= MVPTRW5ITVJ?
CFPAC-1 NGH5Z5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDQcVNKSzVyPUGxMlk4QDJizszN M4PofXNCVkeHUh?=
EKVX MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGCzTWdKSzVyPUGyMlA{OTNizszN MXfTRW5ITVJ?
CAL-51 NVnLPWdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33xbGlEPTB;MUKuNFcyPiEQvF2= NVH4NnRRW0GQR1XS
BB49-HNC NWjxS4JoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETBbZFKSzVyPUGyMlEyPzdizszN NIDiOY1USU6JRWK=
RPMI-7951 NV7hN2RTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjzTWM2OD1zMj6xPFU1KM7:TR?= MYDTRW5ITVJ?
RH-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfPS2psUUN3ME2xNk4zOTh2IN88US=> MmT5V2FPT0WU
BCPAP M4jS[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHmUI5KSzVyPUGyMlQ4PDlizszN M1uxVXNCVkeHUh?=
GCIY NVnx[JhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nkV2lEPTB;MUKuOVIxQSEQvF2= M2f2SHNCVkeHUh?=
KNS-81-FD MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHETWM2OD1zMj61PFY6KM7:TR?= NY\pUWVLW0GQR1XS
KYSE-140 MorMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2D4dWlEPTB;MUKuPFU6PSEQvF2= NEnDSYdUSU6JRWK=
Ca-Ski M{HHOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrsTWM2OD1zMj65NFQyKM7:TR?= NYKzSoEyW0GQR1XS
TGBC1TKB M{frdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGn4UpZKSzVyPUGyMlkyOTVizszN MonJV2FPT0WU
HCC1187 M4fEN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHH0XphKSzVyPUGzMlE6OTJizszN M3;0PXNCVkeHUh?=
SJSA-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInYWVNKSzVyPUGzMlI{OjdizszN NHX5VZhUSU6JRWK=
CTV-1 NFT5Ro1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnOzTWM2OD1zMz6zOFUh|ryP NFe2e2dUSU6JRWK=
WM-115 NFO3T4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvBSlRKSzVyPUGzMlY1QDNizszN MnzOV2FPT0WU
CHP-212 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\iTWM2OD1zMz65O|M6KM7:TR?= NHvn[WFUSU6JRWK=
SCC-15 MmD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jEdWlEPTB;MUOuPVc4PSEQvF2= MlfrV2FPT0WU
BPH-1 M3L2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHJTWM2OD1zND6xOlY1KM7:TR?= Ml3qV2FPT0WU
SW780 NX\INoJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTF2LkWwNlUh|ryP NH7BNo1USU6JRWK=
NCI-H2291 MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;5V2lEPTB;MUSuOVg4QCEQvF2= Ml\YV2FPT0WU
JEG-3 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LIcWlEPTB;MUSuOlMzPiEQvF2= M2S0RXNCVkeHUh?=
CAL-120 M{\5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1v5N2lEPTB;MUSuO|AzPyEQvF2= MYDTRW5ITVJ?
NCI-H23 NEWxPJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\DNGlEPTB;MUSuO|k6PyEQvF2= NFy2bGxUSU6JRWK=
MS-1 M3fKWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn61TWM2OD1zND65OlEyKM7:TR?= M3vBUHNCVkeHUh?=
PC-14 NH7qZm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\QVYdKSzVyPUG0Mlk3PTRizszN NXrUO5AxW0GQR1XS
D-283MED MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTF3LkCxNVEh|ryP M3TXcHNCVkeHUh?=
OE19 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTF3LkG1OFEh|ryP MmrrV2FPT0WU
CAS-1 NWHGXFMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTF3LkSxPFQh|ryP MXzTRW5ITVJ?
NCI-H727 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTF3LkSyNlEh|ryP MYjTRW5ITVJ?
SiHa NXLvNpB6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PnZWlEPTB;MUWuO|U6PCEQvF2= MWnTRW5ITVJ?
BFTC-905 MnP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nQWGlEPTB;MUWuO|Y6PCEQvF2= NIf5cVZUSU6JRWK=
MDA-MB-453 NXS0bmdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rUZmlEPTB;MU[uNVY1OiEQvF2= M1nOdnNCVkeHUh?=
HuP-T3 NETZfXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYW5PHY4UUN3ME2xOk43Ozd|IN88US=> M3LKdHNCVkeHUh?=
SK-LU-1 NXKw[INtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLZUY9FUUN3ME2xOk43QTV4IN88US=> M{W1fnNCVkeHUh?=
Detroit562 NUjhR3JKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXqzZ2NsUUN3ME2xOk44OzF6IN88US=> NFLISIdUSU6JRWK=
HCC1569 NELX[2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjCZ2d3UUN3ME2xOk45OzN5IN88US=> MUPTRW5ITVJ?
SK-MES-1 MkTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzM[IhOUUN3ME2xOk45PDF7IN88US=> M2Hl[XNCVkeHUh?=
BB65-RCC MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2W4NmlEPTB;MUeuNFQ4QSEQvF2= NUP5XXdTW0GQR1XS
LOXIMVI M4LLVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPmTWM2OD1zNz6wO|A4KM7:TR?= NEHCTGZUSU6JRWK=
SW1783 MmDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3K[YZKSzVyPUG3MlEzQCEQvF2= NW\kdW57W0GQR1XS
NH-12 MlLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XtcGlEPTB;MUeuN|MxOyEQvF2= NGDsNoRUSU6JRWK=
UACC-257 MkDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFW3TZNKSzVyPUG3MlU2OTJizszN MVjTRW5ITVJ?
KOSC-2 NITiOFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfiNFFKSzVyPUG3MlY4PTdizszN NVzWNFRJW0GQR1XS
KG-1 NF3lUXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTF5Lk[5N|ch|ryP M3TIdXNCVkeHUh?=
M059J NFi2UXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\jTWM2OD1zNz63NFMh|ryP M{XyWHNCVkeHUh?=
MHH-NB-11 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ewSWlEPTB;MUeuPVY4OyEQvF2= NWjDT|FxW0GQR1XS
EW-1 NXXGW2c1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTF6LkGzPFIh|ryP MkXZV2FPT0WU
CAL-85-1 M4fyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4H5TmlEPTB;MUiuNlM2PyEQvF2= NEDLRYpUSU6JRWK=
639-V Ml71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTITWM2OD1zOD6zN|U1KM7:TR?= M3TQe3NCVkeHUh?=
C32 NXHqcWdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:yPWlEPTB;MUiuOFczPyEQvF2= NEX2e5VUSU6JRWK=
KM-H2 NGHIdHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\CRYVKSzVyPUG4MlUzOzJizszN NWHvcHJwW0GQR1XS
A253 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTF6LkeyPFYh|ryP MYLTRW5ITVJ?
NCI-N87 M1HG[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX:0WXdrUUN3ME2xPE46ODB6IN88US=> MkXpV2FPT0WU
8-MG-BA M161fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rURmlEPTB;MUmuNFY1PiEQvF2= M{LObXNCVkeHUh?=
GI-ME-N M2jqcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTF7LkG1OFYh|ryP M4GyVnNCVkeHUh?=
8305C NInoNW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlq0TWM2OD1zOT6yNlg3KM7:TR?= M{PiRnNCVkeHUh?=
TE-8 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLJUYtqUUN3ME2xPU4{ODJ2IN88US=> MYXTRW5ITVJ?
KYSE-270 NGrNPW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPNTZRKSzVyPUKwMlAzOTdizszN MkjFV2FPT0WU
HL-60 MkDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTJyLkC5OFEh|ryP MVrTRW5ITVJ?
Mo-T M{nxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mln5TWM2OD1{MD6xOlY2KM7:TR?= NGj2OWJUSU6JRWK=
NCI-H1355 NWq3ZY5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTJyLkOzO|Qh|ryP MkXpV2FPT0WU
HT-1080 NXrFfXdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXseWpKSzVyPUKwMlU1QTdizszN NH;aeXBUSU6JRWK=
MIA-PaCa-2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TTVWlEPTB;MkCuOlg5OyEQvF2= M1e4dXNCVkeHUh?=
NCI-H441 NYq3fYMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELy[WVKSzVyPUKwMlc{PzlizszN NFPB[XlUSU6JRWK=
LCLC-97TM1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTJyLkixN|Qh|ryP NIHse5JUSU6JRWK=
HT-3 NITXeYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fRVmlEPTB;MkGuOVY{OSEQvF2= MkniV2FPT0WU
22RV1 MmTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LSZWlEPTB;MkGuOVY5PSEQvF2= NVvuN5R4W0GQR1XS
LK-2 NG\wbW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17ncWlEPTB;MkGuOVk2OyEQvF2= NWjNZopxW0GQR1XS
CW-2 M4DlO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnP6TWM2OD1{MT62NFY6KM7:TR?= M4\jN3NCVkeHUh?=
KYSE-510 NWrqRnFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPwWFRKSzVyPUKxMlYxQTVizszN M2\XS3NCVkeHUh?=
CGTH-W-1 M1zPOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;TTWM2OD1{MT63NVY3KM7:TR?= MnGxV2FPT0WU
NCI-H661 MoH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTtXFBKSzVyPUKyMlA{PCEQvF2= MnHDV2FPT0WU
KU-19-19 M4nL[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;JcnZnUUN3ME2yNk4yPjl5IN88US=> M17TTnNCVkeHUh?=
NCI-H2122 MoLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jUXWlEPTB;MkKuNlQ{OiEQvF2= MXrTRW5ITVJ?
NCI-H526 MnfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULxNmI1UUN3ME2yNk4{QDl3IN88US=> M2HhUHNCVkeHUh?=
NCI-H1650 M1rRPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTJ{Lke2OEDPxE1? NUfvXm5UW0GQR1XS
AM-38 MofiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonsTWM2OD1{Mj64Olg6KM7:TR?= M3zHR3NCVkeHUh?=
NCI-H2405 MnT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13kZmlEPTB;MkOuNlU{OyEQvF2= NWntTm5EW0GQR1XS
M14 NHjucJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfFTWM2OD1{Mz60NFg5KM7:TR?= MnmwV2FPT0WU
ES4 M1LQOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzyco5PUUN3ME2yN{41OjN{IN88US=> M4TESnNCVkeHUh?=
DJM-1 M4fhN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV32RpRnUUN3ME2yN{42OjN2IN88US=> MUHTRW5ITVJ?
S-117 NH3EZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1z5fGlEPTB;MkOuO|Y2OSEQvF2= MWXTRW5ITVJ?
MZ2-MEL NIjxU3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXj2b5NtUUN3ME2yN{44PzV7IN88US=> Mm\TV2FPT0WU
SK-MEL-2 NWjIOWw{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;F[JdxUUN3ME2yN{45OTN|IN88US=> NYC1UYhDW0GQR1XS
HCC1806 NIjHR5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrDTWM2OD1{Mz64O|A6KM7:TR?= NF3RT4lUSU6JRWK=
NMC-G1 M1\tWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTJ2LkKyNlYh|ryP NX7pdI9NW0GQR1XS
DK-MG NGe3V2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnRTWM2OD1{ND6yPVQh|ryP M1zNd3NCVkeHUh?=
SK-N-FI M2OzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrHT2pbUUN3ME2yOE4{OzB{IN88US=> MV3TRW5ITVJ?
KINGS-1 NH7IXGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\1O4x3UUN3ME2yOE41QDd2IN88US=> Mn\zV2FPT0WU
HCC2998 NYTRPXhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTJboFKSzVyPUK0MlQ5QDVizszN MWrTRW5ITVJ?
ALL-PO NF;zTJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXQTWM2OD1{ND62NVkh|ryP MoDDV2FPT0WU
MPP-89 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXub3hKSzVyPUK1MlA1PThizszN M{XSfHNCVkeHUh?=
NCI-H2342 NFPUNldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rR[mlEPTB;MkWuNVk2OyEQvF2= MYfTRW5ITVJ?
TE-1 NITLRoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTX[21KSzVyPUK1MlM2PjNizszN NIfERoNUSU6JRWK=
RH-18 MnjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTJ3LkW5NVgh|ryP NV3JPZR4W0GQR1XS
HT-1376 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\SN4JtUUN3ME2yOU43PDZ3IN88US=> NXm5TpV[W0GQR1XS
U-2-OS M3\wTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXoT2NkUUN3ME2yOU43QDh6IN88US=> NU\kcoRGW0GQR1XS
BT-549 M{f2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGD5XlNKSzVyPUK1MlkxOTFizszN MnvVV2FPT0WU
NCI-H1755 M{jQdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDOTWM2OD1{NT65PVQ2KM7:TR?= NGLpbIFUSU6JRWK=
EW-13 M1WxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfMVXNKSzVyPUK2MlAzPzRizszN NIfuRVNUSU6JRWK=
NB13 NWiyR5VmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTJ4LkC5OFkh|ryP MnzBV2FPT0WU
NUGC-3 NXfm[owzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\jcZF1UUN3ME2yOk4zOTB|IN88US=> M3HDZ3NCVkeHUh?=
GMS-10 NGLtfm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPi[WJKSzVyPUK2MlI{PTNizszN NVnBenN[W0GQR1XS
CHP-134 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFf2bolKSzVyPUK2MlM5PjdizszN M3PwZ3NCVkeHUh?=
SW962 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjnZXdWUUN3ME2yOk42ODJzIN88US=> NFLJ[HdUSU6JRWK=
SNU-449 M1:2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrpfJBPUUN3ME2yO{4xQDB|IN88US=> MnTrV2FPT0WU
HuP-T4 NGOy[3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrHTWM2OD1{Nz6wPFc6KM7:TR?= M1TkbHNCVkeHUh?=
SW948 M{jBXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTJ5LkGzOFQh|ryP NH:yTYNUSU6JRWK=
NCI-H226 M{D4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTJ5LkS1O|gh|ryP NIXHZlNUSU6JRWK=
SK-PN-DW M1\LWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknZTWM2OD1{Nz62NFEzKM7:TR?= Ml;ZV2FPT0WU
GI-1 NYnHT5E2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGryN3RKSzVyPUK3MlczOSEQvF2= M{fYNnNCVkeHUh?=
CAL-12T MoLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PjcmlEPTB;MkiuNVEyOiEQvF2= MYHTRW5ITVJ?
YAPC M4Kycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELXSGFKSzVyPUK4MlI2PjRizszN NGryd3pUSU6JRWK=
SNU-C2B NWizOm5HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTJ6LkK5OlQh|ryP NHnvPXBUSU6JRWK=
RCC10RGB NEPiVY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjJTZdKSzVyPUK4MlU1OTdizszN M2\O[XNCVkeHUh?=
ES7 M3zpcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGL5d5hKSzVyPUK5MlE1PjVizszN NFvjSplUSU6JRWK=
PANC-03-27 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4P1NWlEPTB;MkmuOFQ1KM7:TR?= Mo\RV2FPT0WU
ES6 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnGc2xKSzVyPUK5MlgyPTdizszN NIPTSFBUSU6JRWK=
HT-1197 M2LSTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTNyLkC1PVgh|ryP Mo\WV2FPT0WU
ZR-75-30 NGnpZldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHPR3NKSzVyPUOwMlI{QDNizszN NVfT[pI5W0GQR1XS
DB NFPzbZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTNyLkS5OFIh|ryP NVfifGxCW0GQR1XS
OCI-AML2 NXS0dpBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DDZ2lEPTB;M{GuNFY6KM7:TR?= Mm\rV2FPT0WU
NCI-H2170 M{H0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3TUpFKSzVyPUOxMlg2OTZizszN NHzhclRUSU6JRWK=
IST-MES1 NI\UVZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LVWmlEPTB;M{KuNlg6PyEQvF2= NEP2cHFUSU6JRWK=
769-P MmfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HhdmlEPTB;M{KuN|Y1OSEQvF2= NG\jT3pUSU6JRWK=
COR-L23 MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTN{LkmwO|Mh|ryP MUPTRW5ITVJ?
SW626 Mmf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInMWZdKSzVyPUOzMlE4PzZizszN M3[4e3NCVkeHUh?=
LU-139 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7oT|U3UUN3ME2zN{43PjB3IN88US=> MlywV2FPT0WU
HT-144 M1HhSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXe3bVBXUUN3ME2zN{45PjNizszN NWPNXGd6W0GQR1XS
CaR-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3WbolKSzVyPUOzMlk5OjJizszN NHrCToRUSU6JRWK=
OE33 MoDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLGN2tzUUN3ME2zOE4zQDV3IN88US=> MXnTRW5ITVJ?
COLO-800 NYW2TmF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXCTWM2OD1|ND6zOlQ4KM7:TR?= MX7TRW5ITVJ?
NB14 M{jlXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HyemlEPTB;M{SuOFY5PCEQvF2= NYnMfoZpW0GQR1XS
KURAMOCHI NV3QcYIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vUN2lEPTB;M{[uNVE6QCEQvF2= M1\WN3NCVkeHUh?=
SW48 NU\Yb4VnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknvTWM2OD1|Nj6yOFc1KM7:TR?= MYDTRW5ITVJ?
Daoy M1zzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4H4UmlEPTB;M{[uOlU{QCEQvF2= NVTjOYpnW0GQR1XS
TGBC24TKB MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTN4Lk[3JO69VQ>? NWn4bGpvW0GQR1XS
DU-4475 MnHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfiTWM2OD1|Nj65NFM{KM7:TR?= NIjPeoZUSU6JRWK=
SW1417 MkPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLqepBKSzVyPUO4MlA2PTJizszN M2fuU3NCVkeHUh?=
EFO-21 M1XMd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX[3WWhSUUN3ME2zPE46OzR7IN88US=> NWq0N45GW0GQR1XS
MG-63 M3fNUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXRXGZPUUN3ME2zPU4{PDJ2IN88US=> NH3ZZ5NUSU6JRWK=
LC-2-ad Mn\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHK2fmtKSzVyPUO5MlU2OTJizszN NVTvfnhHW0GQR1XS
NOMO-1 M2nJOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTN7LkiyO|Qh|ryP MnTlV2FPT0WU
COLO-741 NV\mToRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DwWmlEPTB;NECuNVMxPCEQvF2= MknrV2FPT0WU
BxPC-3 MlS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHTTWM2OD12MD61Olg3KM7:TR?= M{O4O3NCVkeHUh?=
HSC-2 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;adlhiUUN3ME20NE46OTF|IN88US=> M{\Eb3NCVkeHUh?=
UMC-11 MnvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\kWZBMUUN3ME20NU4zPjNizszN NVjrWI5RW0GQR1XS
HCC1937 M4\yPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTR{Lke4OFMh|ryP MVXTRW5ITVJ?
Calu-6 NYX0dJJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnKe4FRUUN3ME20N{4zOzh{IN88US=> MoLRV2FPT0WU
NCI-H1573 MnH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTR|LkO0O|ch|ryP MmP5V2FPT0WU
SK-N-AS NW[ydYJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnvbVVKSzVyPUSzMlYxOTlizszN NXLGcFNLW0GQR1XS
PSN1 M1j5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGW3WJBKSzVyPUS1MlI2PDhizszN NV\meWI{W0GQR1XS
TE-11 Ml\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPFWVVKSzVyPUS1MlQ5PDJizszN NE\wW|ZUSU6JRWK=
NCI-H1155 M{C0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrMclZzUUN3ME20OU45QTZ5IN88US=> NYnpdJlqW0GQR1XS
KM12 NXfJPXJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXueZdEUUN3ME20OU46ODd4IN88US=> MkDiV2FPT0WU
RO82-W-1 NFzVSpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLmWnVKSzVyPUS2Mlk5OjJizszN M4Xob3NCVkeHUh?=
SW1573 NInlVGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXjTWM2OD12Nz6zO|M3KM7:TR?= NFS1RZJUSU6JRWK=
CAKI-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlizTWM2OD12OD6yPFQ2KM7:TR?= MlO3V2FPT0WU
U-118-MG M2G3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTR6LkO3NFIh|ryP MWLTRW5ITVJ?
KYSE-520 MnLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTR6LkSwNVYh|ryP MUXTRW5ITVJ?
HT55 NEf1SmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPZOGlKSzVyPUS5MlE1PzRizszN MVPTRW5ITVJ?
ChaGo-K-1 NIS1[nZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;HUWlEPTB;NEmuOFc6OyEQvF2= Ml;HV2FPT0WU
IA-LM NVfYXo1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\ndXdKSzVyPUW0MlY{OjJizszN Mo\XV2FPT0WU
UACC-62 NUnkXnNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPkV2NKSzVyPUW1MlExPDZizszN NWrMd2V6W0GQR1XS
MKN7 M1TMWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTV4LkCyPFUh|ryP MnrxV2FPT0WU
HPAF-II MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTV4LkSwO|Mh|ryP NYfrbFdTW0GQR1XS
NTERA-S-cl-D1 M1K0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTV5Lke3PEDPxE1? MUPTRW5ITVJ?
FTC-133 MnLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfuXW1KSzVyPUW4MlA6PjlizszN NEX6dmtUSU6JRWK=
MHH-ES-1 NYrHN5RIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDKPGx5UUN3ME21PE41QDF2IN88US=> M1zNWnNCVkeHUh?=
JVM-2 NFHIZ25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XkcGlEPTB;NUiuPVUxPiEQvF2= MXLTRW5ITVJ?
TCCSUP NFTBfHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfpTWM2OD13OT61Nlc6KM7:TR?= NV\RcoZZW0GQR1XS
COLO-824 NYO4UW9lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LH[WlEPTB;NkCuNFcyQSEQvF2= MkL6V2FPT0WU
647-V MmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\kNFJ3UUN3ME22NE4yOzR5IN88US=> M3WxOHNCVkeHUh?=
HD-MY-Z NHX1eYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jFbmlEPTB;NkCuOVI6PCEQvF2= MVfTRW5ITVJ?
LS-411N NGfaSJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTZzLkO5NFMh|ryP MnTtV2FPT0WU
NCI-H596 MlXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\2[2p2UUN3ME22Nk44PDl4IN88US=> M{XGb3NCVkeHUh?=
C-33-A MoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTZ2LkC5OVch|ryP NXzRcW1OW0GQR1XS
BHY NVThfFRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HPWmlEPTB;NkSuNVI1PSEQvF2= NHn3NItUSU6JRWK=
KGN MkfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWL2NYVOUUN3ME22OE42PTF2IN88US=> M{LjWnNCVkeHUh?=
NCI-H1092 NGW4bVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWL3UYg{UUN3ME22OU4xODl3IN88US=> MXfTRW5ITVJ?
MZ1-PC NYTaXXNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TQe2lEPTB;NkWuOVY1QSEQvF2= Mn\LV2FPT0WU
LB831-BLC MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPZSpVKSzVyPU[1Mlg1QDFizszN MlzjV2FPT0WU
SW620 M2TKWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrmcXlKSzVyPU[2MlIxOzlizszN Mn\PV2FPT0WU
HuO-3N1 M{HYfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfpXY9OUUN3ME22PE4{OjN6IN88US=> NXz6b4dqW0GQR1XS
SK-HEP-1 M2f2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HTSGlEPTB;NkmuPVQ5PiEQvF2= MmSyV2FPT0WU
LCLC-103H NHm0Wm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTdyLk[3NFUh|ryP Mlq3V2FPT0WU
KYSE-70 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDrTWM2OD15MD63PFM2KM7:TR?= NFPEb2pUSU6JRWK=
Mewo M37KO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\sTWM2OD15MT61NFUh|ryP NFyzRlJUSU6JRWK=
COLO-668 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTdzLki0OVEh|ryP MW\TRW5ITVJ?
NCI-H522 M33qOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvLcoVKSzVyPUeyMlM1OTNizszN M1vPR3NCVkeHUh?=
NCI-H1437 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDEdnExUUN3ME23OE41ODR6IN88US=> MljKV2FPT0WU
U-266 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;1UGlEPTB;N{WuOFUyPiEQvF2= M3T3WnNCVkeHUh?=
MC116 NV25OVJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTd3LkW3NFgh|ryP NYDlenljW0GQR1XS
PANC-10-05 NWP1RlN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYT6O29yUUN3ME23O{41OjR|IN88US=> M4myZnNCVkeHUh?=
KYSE-180 MnHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTd5LkW0OVQh|ryP M{LOOnNCVkeHUh?=
JAR NFPTeZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTd7LkC1OFYh|ryP NVnQdWw2W0GQR1XS
CAL-62 M1\5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIq1bHpKSzVyPUiwMlA6PSEQvF2= MnXCV2FPT0WU
A3-KAW NHr1TVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRThyLkKxOVQh|ryP M2OzVXNCVkeHUh?=
PANC-08-13 NG[1ZXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37W[GlEPTB;OEGuNVc3QCEQvF2= MYPTRW5ITVJ?
HSC-3 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULDWll2UUN3ME24N{4{ODdzIN88US=> NX3oS4VUW0GQR1XS
HTC-C3 M4n1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTh|LkS3NFIh|ryP MV3TRW5ITVJ?
KY821 MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTh2LkC4PVIh|ryP NV\WVoxtW0GQR1XS
DoTc2-4510 NX;XOZN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTh2LkKxPFUh|ryP MkOzV2FPT0WU
NCI-H1581 NYrwPGJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVq4cFdbUUN3ME24OU41PjRzIN88US=> NH;BdVNUSU6JRWK=
KARPAS-299 NITwdmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTh4LkG5O|ch|ryP NF33c2RUSU6JRWK=
IST-MEL1 MnzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTh4Lki4O|Ih|ryP MUTTRW5ITVJ?
KP-N-YS NXrh[JB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTh7LkmwNlgh|ryP NFvHZ4FUSU6JRWK=
KYSE-410 NHLoXm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXoTWM2OD17MT60NFQzKM7:TR?= Mo\VV2FPT0WU
TE-10 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;XOWlEPTB;OUGuOVYyOSEQvF2= MnvBV2FPT0WU
SK-MEL-1 Mm\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3sUIhKSzVyPUmyMlkyODZizszN MlfYV2FPT0WU
COLO-792 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWK1dnBoUUN3ME25OU4zPTZ2IN88US=> NHL6[VRUSU6JRWK=
SCH MlvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXETWM2OD17Nj6zPFc4KM7:TR?= MnfDV2FPT0WU
NCI-H1792 MmOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37qWmlEPTB;OU[uPFk6OiEQvF2= NIr1c5pUSU6JRWK=
NCI-H2029 MojzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XPTWlEPTB;OU[uPVU3PiEQvF2= NIDlRXdUSU6JRWK=
SW684 NEDHNXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Xr[2lEPTB;OUiuOlY2PCEQvF2= NInDNpJUSU6JRWK=
NCI-H209 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3u1VGlEPTB;MUCwMlEzOSEQvF2= MlzOV2FPT0WU
HLE MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPXTWM2OD1zMEWuNlgzKM7:TR?= Mny4V2FPT0WU
GOTO NUHVUYQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfFR5ZFUUN3ME2xNFcvPzd5IN88US=> MlHmV2FPT0WU
NCI-H1793 NEDYVVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXYTWM2OD1zMEmuNlgh|ryP NWDsO5hkW0GQR1XS
D-392MG MlrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\4[nhSUUN3ME2xNVcvOzl6IN88US=> NEDP[WRUSU6JRWK=
SW1990 NH73T4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\0U2NKSzVyPUGyNE46PTFizszN MlTwV2FPT0WU
ML-2 NHTnV5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHObpBRUUN3ME2xNlEvPjd4IN88US=> M{jscHNCVkeHUh?=
NCI-H2452 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTF{Mj6yNUDPxE1? M2rUW3NCVkeHUh?=
SK-MEL-30 M3e5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2G2bmlEPTB;MUKzMlI1PCEQvF2= MlHBV2FPT0WU
SN12C MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;GbW1KSzVyPUGyOE4yPzZizszN NXLTNI9UW0GQR1XS
NCI-H1770 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvMU4s3UUN3ME2xNlUvPTF2IN88US=> NXf6VJoyW0GQR1XS
SF268 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TTN2lEPTB;MUK2MlE2QCEQvF2= NWLNeZdGW0GQR1XS
BALL-1 MmDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfvVVJKSzVyPUGyOk4zOyEQvF2= NWj4SI1SW0GQR1XS
COLO-679 NGTLR4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LrNGlEPTB;MUK2Mlc2OyEQvF2= NHXkT4NUSU6JRWK=
A2780 M1\URmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\Fd|RKSzVyPUGyPE46QDhizszN MmfCV2FPT0WU
NCI-H1651 NH;1dlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXWdVNKSzVyPUGzNU4zPDNizszN NUHuUmlvW0GQR1XS
NCI-H2087 M123Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rWPGlEPTB;MUOxMlQ5OyEQvF2= NHWzU49USU6JRWK=
U-87-MG NInvbm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTF|Mz62NFQh|ryP MXPTRW5ITVJ?
LB2518-MEL NHTGdJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTF|NT65PVMh|ryP NGnKW2JUSU6JRWK=
HCT-116 MmfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnGzTWM2OD1zM{euNlE4KM7:TR?= MXXTRW5ITVJ?
Ca9-22 NGLiZllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\yVWxKSzVyPUGzPU45OzNizszN NHXZepZUSU6JRWK=
COR-L88 MkLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDu[GhKSzVyPUG0Nk4yPCEQvF2= MmKwV2FPT0WU
CP50-MEL-B Mom3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4X6RWlEPTB;MUS0MlUxOSEQvF2= MYXTRW5ITVJ?
OVCAR-8 NUXJNG9TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjxbIhKSzVyPUG0OU43OzZizszN M{\pW3NCVkeHUh?=
SK-MEL-3 NWLIeJVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml:0TWM2OD1zNEeuPFc5KM7:TR?= M2XKcnNCVkeHUh?=
GT3TKB NXH0V49CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXm1fmNJUUN3ME2xOFkvQTJ6IN88US=> M1q0cXNCVkeHUh?=
KYSE-450 NUjWXpd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjRWWlqUUN3ME2xOVEvPTN7IN88US=> M2fvOXNCVkeHUh?=
CAPAN-1 M1TXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTC[nd7UUN3ME2xOVMvODZ2IN88US=> NHzVV|BUSU6JRWK=
BEN MmnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlS1TWM2OD1zNUOuPVI5KM7:TR?= MofJV2FPT0WU
NCI-H1304 MmHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTF3ND62PVQh|ryP Mn;zV2FPT0WU
KU812 M3G0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvZTWM2OD1zNUiuOlc1KM7:TR?= M2DyfHNCVkeHUh?=
Capan-2 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlv0TWM2OD1zNkCuOVU{KM7:TR?= Mm\pV2FPT0WU
A673 MlrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zoZWlEPTB;MU[xMlcxPSEQvF2= NX6yZph2W0GQR1XS
SAS Ml\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHJTWM2OD1zNkKuOlc5KM7:TR?= MnTPV2FPT0WU
NY MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnEUHpKSzVyPUG2OU4{OTRizszN NYniU4NpW0GQR1XS
HCE-4 MkXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvXTWM2OD1zNk[uPFQ2KM7:TR?= NX\IWXkzW0GQR1XS
MDA-MB-231 NX;PbY5DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjTRnlKSzVyPUG3O{42ODNizszN NUOz[3lWW0GQR1XS
no-10 MljqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13CPGlEPTB;MUe4MlE{PCEQvF2= M4mxO3NCVkeHUh?=
MZ7-mel MlX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnOTWM2OD1zN{iuOFY4KM7:TR?= NXzW[mhYW0GQR1XS
NCI-H82 M{TkdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTF6MD6xOlUh|ryP M3zGO3NCVkeHUh?=
CAL-72 NY\sVIlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTF6NT6wOVQh|ryP Mm\xV2FPT0WU
NCI-SNU-5 MonZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HDeGlEPTB;MUi2Mlg1KM7:TR?= MY\TRW5ITVJ?
OVCAR-4 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIP0TVhKSzVyPUG4PE4{OzNizszN MoTEV2FPT0WU
SCC-9 NEXLTlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnlemdQUUN3ME2xPVEh|ryP MkHOV2FPT0WU
KYSE-150 M{Dm[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEe4Z|ZKSzVyPUG5NU45QDhizszN M37CNnNCVkeHUh?=
HT-29 NIGyb4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnu5TWM2OD1{MEGuNlEzKM7:TR?= MWXTRW5ITVJ?
COLO-678 M{juWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJyMT60OUDPxE1? MXTTRW5ITVJ?
NCI-H650 MonWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPJUFlKSzVyPUKwNk4yODNizszN NUn4OnZuW0GQR1XS
HuCCT1 M1vlc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nKfGlEPTB;MkC0MlIxQCEQvF2= NGTHZ2xUSU6JRWK=
SW1116 NGDIXldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\MTWM2OD1{MEeuNFc4KM7:TR?= MWrTRW5ITVJ?
DBTRG-05MG MoS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF:1U2pKSzVyPUKwO{46ODlizszN Mn\LV2FPT0WU
SW982 NGDU[4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2e2bmlEPTB;MkC3Mlk1QCEQvF2= M{HaV3NCVkeHUh?=
RCM-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTJzND63OlIh|ryP MlrvV2FPT0WU
COLO-320-HSR MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TzV2lEPTB;MkG2MlEzPSEQvF2= MWjTRW5ITVJ?
KNS-42 NHjHem5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfHSphJUUN3ME2yNVYvPTd2IN88US=> NVSyeW5HW0GQR1XS
C2BBe1 Ml7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3nOFJKSzVyPUKzNU46ODVizszN NITnOWNUSU6JRWK=
CCRF-CEM NWO4UZB6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vjZ2lEPTB;MkSzMlc6PSEQvF2= NXvUSFVsW0GQR1XS
SH-4 MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2r4O2lEPTB;MkS2MlA6KM7:TR?= NVXrcFhyW0GQR1XS
LS-1034 NFS4fVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTJ2Nj6yOlYh|ryP NGnHdIlUSU6JRWK=
NCI-H2347 NUTnd2NFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fpWGlEPTB;MkS3MlcyOyEQvF2= M33McnNCVkeHUh?=
RPMI-8866 MnTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\5OWlEPTB;MkS5MlI4KM7:TR?= MYTTRW5ITVJ?
GAK M1vNWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHITWM2OD1{NUOuNFAzKM7:TR?= MofuV2FPT0WU
NB6 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTJ5MD6xJO69VQ>? NYTaNYx3W0GQR1XS
COLO-680N MnvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWOybFRGUUN3ME2yO|IvPTJ5IN88US=> NInvfZlUSU6JRWK=
RERF-LC-MS M2S0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4e5PGlEPTB;Mke2MlAxPyEQvF2= MX\TRW5ITVJ?
TGBC11TKB M1nNUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfaXWdKSzVyPUK3PE4yPzhizszN M1;ocXNCVkeHUh?=
C8166 NWflbZpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1:2[2lEPTB;Mke4MlUxPiEQvF2= M13sXHNCVkeHUh?=
HDLM-2 Mly3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTJ7ND60NFkh|ryP Ml;qV2FPT0WU
IGR-1 NEDHT25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTJ7NT62OVkh|ryP MYDTRW5ITVJ?
FADU M4S3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTJ7Nz61NUDPxE1? MV3TRW5ITVJ?
L-428 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYT1eZRNUUN3ME2yPVcvPjF4IN88US=> MVjTRW5ITVJ?
LU-65 NV24WoM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTNyND6zNkDPxE1? NUnDOpByW0GQR1XS
HEL M4SxSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\0TWM2OD1|MEmuPVg{KM7:TR?= NYnlNWRxW0GQR1XS
NCI-H810 M{jHN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\QTWM2OD1|MUCuOVch|ryP MXjTRW5ITVJ?
C3A M1r5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVn0OFRyUUN3ME2zNVEvQDB{IN88US=> MYnTRW5ITVJ?
NCI-H630 NULGbFhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLZTWM2OD1|M{KuNlk1KM7:TR?= MWnTRW5ITVJ?
KP-N-YN NYrSfodqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\sVWlEPTB;M{SxMlEzOyEQvF2= NFz5UpVUSU6JRWK=
MOLT-13 NFX2VmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1qwOWlEPTB;M{SyMlMzPiEQvF2= MlPaV2FPT0WU
NCI-H1993 NULpUVFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXJNHVKSzVyPUO0Nk4{PjVizszN NYTmSpB2W0GQR1XS
BE-13 NHXONpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVmwUFhHUUN3ME2zOFQvOTZ5IN88US=> MlPRV2FPT0WU
IST-SL1 MoXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3v3VGlEPTB;M{S3MlQxOSEQvF2= MWDTRW5ITVJ?
TE-9 MlHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHQZYFkUUN3ME2zOlMvPTh7IN88US=> NVq2NZdNW0GQR1XS
LU-135 MkHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjHXJVKSzVyPUO2O{4xOzVizszN MXzTRW5ITVJ?
T84 NH;KSndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTiTWM2OD1|N{SuO|EzKM7:TR?= NV;tenhSW0GQR1XS
K-562 M3;rfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\NW2lEPTB;M{izMlM3KM7:TR?= NETRTmNUSU6JRWK=
SBC-5 Mnf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjGclZ{UUN3ME2zPFYvQTh3IN88US=> M4HhT3NCVkeHUh?=
NB17 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTN7Mj61PVYh|ryP NXLwZ2FWW0GQR1XS
NCI-H2052 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTN7OD60O|Ih|ryP M3zscHNCVkeHUh?=
HCC38 NFi4VIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPuXVBtUUN3ME20NFEvPTl|IN88US=> M4fMd3NCVkeHUh?=
NCI-H69 M{f2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvnW49KSzVyPUS0NU4xQDNizszN NW\TWFN[W0GQR1XS

... Click to View More Cell Line Experimental Data
In vivo MK-2206 shows 60% TGI and inhibits more than 70 % of phospho-Akt1/2 (T308 and S473) in A2780 ovarian cancer xenografts at a dose of 240 mg/kg. [1] MK-2206 exhibits significant antitumor activity in NCI-H292 xenograft in combination with erlotinib or lapatinib. [2]

Protocol

Kinase Assay:

[4]
+ Expand

Akt kinases assay:

Akt kinases are assayed by a GSK-derived biotinylated peptide substrate. The extent of peptide phosphorylation is determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide. When the Lance and APC are in proximity, a non-radiative energy transfer takes place from the Lance to the APC, followed by emission of light from APC at 655 nm. Working Solution: 100X protease inhibitor cocktail (PIC): 1mg/mL benzamidine, 0.5 mg/mL pepstatin, 0.5 mg/mL leupeptin, 0.5 mg/mL aprotinin; 10X assay buffer: 500 mM HEPES, pH7.5, 1% PEG, 16.6 mM EDTA, 1 mM EGTA, 1% BSA, 20 mM 9-glycerol phosphate; Quench buffer 50 mM HEPES pH 7.3, 16.6 mM EDTA, 0.1% BSA, 0.1% Triton X-100, 0.17 nM labeled monoclonal antibody, 0.0067 mg/mL SA-APC; ATP/MgCl2 working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, active Akt; Peptide working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, 2 TM GSK biotinylated peptide. The reaction is assembled by adding 16 µL of ATP/MgCl2 working solution to the appropriate wells. MK-2206 or vehicle (1.0 µL) is added followed by 10 µL of peptide working solution. The reaction is started by adding 13 μL of the enzyme working solution and mixing. The reaction is allowed to proceed for 50 min and then stopped by the addition of 60 µL HTRF quench buffer. The stopped reactions are incubated at room temperature for at least 30 min and then read in the instrument.
Cell Research:

[2]
+ Expand
  • Cell lines: A431, HCC827, NCI-H292, NCI-H358, NCI-H23, NCI-H1299, Calu-6 and NCI-H460 cells
  • Concentrations: 0, 0.3, 1 and 3 μM
  • Incubation Time: 72 or 96 hours
  • Method:

    MK-2206 is dissolved in DMSO as a stock solution and diluted by culture media before use. Cells are seeded at a density of 2-3 × 103 in 96-well plates and incubated for 24 hours. Then MK-2206 (0, 0.3, 1 and 3 μM) is added to the cells. Cell proliferation is determined after 72 or 96 hours.


    (Only for Reference)
Animal Research:

[2]
+ Expand
  • Animal Models: SK-OV-3, NCI-H292, HCC70, PC-3, and NCI-H460 models in male CD1-nude mice
  • Formulation: Formulated in 30% Captisol
  • Dosages: 120 mg/kg
  • Administration: Orally administered
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL (29.14 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
15% Captisol
For best results, use promptly after mixing. 		17 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 480.39
Formula

C25H21N5O.2HCl
CAS No. 1032350-13-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01306045 Recruiting Carcinoma, Non-Small-Cell Lung|Carcinoma, Small Cell Lung|Carcinoma, Thymic National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 21, 2011 Phase 2
NCT01802320 Active, not recruiting Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer National Cancer Institute (NCI) March 2013 Phase 2
NCT01783171 Active, not recruiting Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unresectable Pancreatic Carcinoma National Cancer Institute (NCI) January 2013 Phase 1
NCT01776008 Active, not recruiting Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01859182 Withdrawn Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Extrahepatic Bile Duct|Localized Unresectable Adult Primary Liver Cancer|Metastatic Extrahepatic Bile Duct Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Stage II Gallbladder Cancer|Stage IIIA Gallbladder Cancer|Stage IIIB Gallbladder Cancer|Stage IVA Gallbladder Cancer|Stage IVB Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01705340 Terminated Adenocarcinoma of the Gastroesophageal Junction|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Stage IIIC Breast Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Gastric Cancer|Stage IV Breast Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer National Cancer Institute (NCI) September 2012 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is your recommendation for preparing the solution and how would you deliver it to the mice (i.p. or gavage)?

  • Answer:

    You can resuspend MK-2206 in 15% Captisol at up to 17mg/ml. It's a suspension and is for oral gavage use only.

  • Question 2:

    I would want to know if MK-2206 could cross the blood brain barrier?

  • Answer:

    MK-2206 can cross BBB based on the following reference: https://clinicaltrials.gov/ct2/show/NCT01249105.

selleck catalog

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

  • Selective Akt Inhibitor

    CCT128930 AKT2-selective, IC50=6 nM.

  • Most Potent Akt Inhibitor

    AZD5363 Akt1, IC50=3 nM; Akt2, IC50=8 nM; Akt3, IC50=8 nM.

  • Akt Inhibitor in Clinical Trial

    Perifosine (KRX-0401) Phase III fro relapsed and refractory multiple myeloma.

  • Newest Akt Inhibitor

    AZD5363 Potent inhibitor of all isoforms of Akt (Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM, similar to P70S6K/PKA and lower activity towards ROCK1/2.

Related Akt Products

  • Afuresertib (GSK2110183) New

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • AT13148 New

    AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.

  • SC79 New

    SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.

  • AZD5363

    AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

    Features:Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.

  • Ipatasertib (GDC-0068)

    Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM in cell-free assays, 620-fold selectivity over PKA. Phase 2.

  • GSK690693

    GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. Phase 1.

  • Perifosine (KRX-0401)

    Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

  • A-674563

    A-674563 is an Akt1 inhibitor with Ki of 11 nM in cell-free assays, modest potent to PKA and >30-fold selective for Akt1 over PKC.

    Features:Orally bioavailable compound (achieved by replacing indole of A-443654 with phenyl moiety) and somewhat less selective for Akt over PKA than A-443654.

  • Triciribine

    Triciribine is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.

  • Honokiol

    Honokiol is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Phase 3.

Tags: buy MK-2206 2HCl | MK-2206 2HCl supplier | purchase MK-2206 2HCl | MK-2206 2HCl cost | MK-2206 2HCl manufacturer | order MK-2206 2HCl | MK-2206 2HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID